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Timely reperfusion by means of primary percu­
taneous coronary intervention (PCI) is the most 
effective therapy for limiting myocardial infarct 
size in patients with ST­segment elevation myo­
cardial infarction (STEMI). Although mortality 
in this patient population is falling, the number 
of patients in whom heart failure develops is 
increasing. As such, new treatments are needed 
to reduce myocardial infarct size and to preserve 
left ventricular function, so as to prevent the 
onset of heart failure.
One neglected therapeutic target is myocar­
dial reperfusion injury, the term given to the 
cardiomyocyte death that paradoxically results 
from reperfusion of ischemic myocardium.1 This 
phenomenon is mediated, at least in part, by the 
opening of the mitochondrial permeability tran­
sition pore (PTP) in the first few minutes of re­
perfusion and contributes up to 50% of the final 
myocardial infarct size.2 Crucially, there is cur­
rently no effective therapy for preventing myo­
cardial reperfusion injury in patients with STEMI 
treated by primary PCI.
Inhibiting the opening of the PTP with the 
use of cyclosporine has been shown to reduce 
myocardial infarct size in small and large ani­
mal models.2 Piot et al.3 translated this thera­
peutic approach in patients with STEMI and 
found a reduction in enzymatic myocardial in­
farct size with cyclosporine when it was admin­
istered before reperfusion. As now reported in 
the Journal, the same authors have investigated 
whether this therapeutic approach can improve 
clinical outcomes in this patient group.4
In the multicenter, phase 3 CIRCUS (Does 
Cyclosporine Improve Clinical Outcome in ST 
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Elevation Myocardial Infarction Patients) study, 
970 patients with STEMI were administered either 
an intravenous bolus of cyclosporine (at a dose 
of 2.5 mg per kilogram of body weight) or pla­
cebo control, immediately before reperfusion by 
means of primary PCI. The primary composite 
outcome was the incidence of death from any 
cause, worsening of heart failure after the initial 
hospitalization, rehospitalization for heart fail­
ure, or an increase of 15% or more in the left 
ventricular end­diastolic volume (as assessed by 
means of echocardiography) at 1 year. No sig­
nificant difference between cyclosporine therapy 
and placebo control was observed in the primary 
composite outcome. So why, despite the promis­
ing experimental and clinical data, did cyclospo­
rine have no effect on clinical outcomes?
Several factors may be considered. First, al­
though the experimental data supporting the 
cardioprotective effect of cyclosporine are exten­
sive, not all the studies have been positive.5 The 
clinical evidence in favor of a cardioprotective 
effect is limited to one study in this patient 
group.3 Another study involving patients with 
STEMI who were treated with thrombolysis 
showed no effect with cyclosporine.6
Second, the use of an increase in left ven­
tricular end­diastolic volume as one of the pri­
mary outcomes has to be queried. This outcome, 
for which data were missing in 17% of the pa­
tients, is not a clinical one but a surrogate 
marker of adverse left ventricular remodeling. 
The high incidence of this outcome in this study 
(41 to 43%) would have made it difficult for a 
study with a sample of 970 patients to detect a 
significant difference in the rate of death from 
any cause, worsening of heart failure after the 
initial hospitalization, or rehospitalization for 
heart failure.
Finally, the use of CicloMulsion (NeuroVive 
Pharmaceutical), a new formulation of cyclo­
sporine that was used in this study, instead of 
Sandimmune (Novartis), which was used in the 
original study by Piot et al.,3 may have contrib­
uted to the neutral results. CicloMulsion contains 
a lipid emulsion carrier vehicle, thereby avoiding 
the risk of anaphylaxis that has been associated 
with Sandimmune, which uses an ethanol and 
polyoxyethylated castor oil (Cremophor EL) car­
rier vehicle.
The finding that CicloMulsion did not reduce 
enzymatic myocardial infarct size is problematic 
and might suggest that this formulation of cy­
closporine was ineffective at preventing myocar­
dial reperfusion injury, thereby explaining why it 
had no effect on clinical outcomes. Although 
CicloMulsion has been shown to be similar to 
Sandimmune in terms of bioefficacy,7 there ap­
pear to be no published experimental or clinical 
data showing that it can reduce myocardial in­
farct size. Furthermore, experimental studies in 
animals have shown that the lipid emulsion ve­
hicle can itself inhibit PTP opening and reduce 
myocardial infarct size when it is administered 
at the onset of reperfusion.8 As such, the results 
of the recently completed CYCLE (Cyclosporine A 
in Reperfused Acute Myocardial Infarction) study 
(ClinicalTrials.gov number, NCT01650662), which 
involved 444 patients and used Sandimmune, 
are eagerly awaited — although in that trial the 
primary end point was ST­segment resolution 
rather than clinical outcomes. Curiously, the 
neutral effects of remote ischemic precondition­
ing (an endogenous cardioprotective strategy in­
duced by transient limb ischemia and reperfu­
sion) on clinical outcomes after cardiac bypass 
surgery9 have been potentially attributed to the 
use of propofol, another agent that uses lipid 
emulsion as the carrier vehicle.10
In summary, although the results of the 
CIRCUS study are disappointing, they do not 
disprove the existence or clinical significance 
of myocardial reperfusion injury, because it ap­
pears that the formulation of cyclosporine used 
in the study might not have been effective at 
preventing myocardial reperfusion injury. If the 
benefits of PTP inhibition are to be harnessed, 
more specific inhibitors will need to be discov­
ered. Therefore, the search to find an effective 
therapy for preventing myocardial reperfusion 
injury and improving clinical outcomes in pa­
tients with reperfused STEMI should continue.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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